The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

被引：1536

作者：

Alatab, Sudabeh ^{[4
]}

Sepanlou, Sadaf G. ^{[4
,7
]}

Ikuta, Kevin ^{[9
,10
]}

Vahedi, Homayoon ^{[4
]}

Bisignano, Catherine ^{[10
]}

Safiri, Saeid ^{[11
,12
]}

Sadeghi, Anahita ^{[4
]}

Nixon, Molly R. ^{[10
]}

Abdoli, Amir ^{[14
]}

Abolhassani, Hassan ^{[5
,15
]}

Alipour, Vahid ^{[17
,18
]}

Almadi, Majid A. H. ^{[20
,21
]}

Almasi-Hashiani, Amir ^{[16
]}

Anushiravani, Amir ^{[4
]}

Arabloo, Jalal ^{[19
]}

Atique, Suleman ^{[22
,23
]}

Awasthi, Ashish ^{[24
,25
]}

Badawi, Alaa ^{[26
,27
]}

Baig, Atif A. A. ^{[28
,29
]}

Bhala, Neeraj ^{[30
,31
,32
]}

Bijani, Ali ^{[33
]}

Biondi, Antonio ^{[34
]}

Borzi, Antonio M. ^{[35
]}

Burke, Kristin E. ^{[36
]}

Carvalho, Felix ^{[37
,38
]}

Daryani, Ahmad ^{[39
]}

Dubey, Manisha ^{[40
]}

Eftekhari, Aziz ^{[13
,42
]}

Fernandes, Eduarda ^{[44
]}

Fernandes, Joao C. ^{[43
]}

Fischer, Florian ^{[45
]}

Haj-Mirzaian, Arvin ^{[3
,48
]}

Haj-Mirzaian, Arya ^{[3
,49
]}

Hasanzadeh, Amir ^{[2
,41
]}

Hashemian, Maryam ^{[50
,51
]}

Hay, Simon, I ^{[8
,10
]}

Hoang, Chi L. ^{[52
]}

Househ, Mowafa ^{[53
,54
]}

Ilesanmi, Olayinka S. ^{[55
]}

Balalami, Nader Jafari ^{[56
]}

James, Spencer L. ^{[10
]}

Kengne, Andre P. ^{[57
,58
]}

Malekzadeh, Masoud M. ^{[4
]}

Merat, Shahin ^{[4
]}

Meretoja, Tuomo J. ^{[59
,60
]}

Mestrovic, Tomislav ^{[61
,62
]}

Mirrakhimov, Erkin M. ^{[63
,64
]}

Mirzaei, Hamed ^{[1
,65
]}

Mohammad, Karzan A. ^{[66
,67
]}

Mokdad, Ali H. ^{[8
,10
]}

机构：

[1] Univ Tehran Med Sci, Dept Med Immunol, Tehran, Iran

[2] Univ Tehran Med Sci, Dept Microbiol, Tehran, Iran

[3] Univ Tehran Med Sci, Dept Pharmacol, Tehran, Iran

[4] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran

[5] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Tehran, Iran

[6] Univ Tehran Med Sci, Shariati Hosp, Tehran, Iran

[7] Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, Iran

[8] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98121 USA

[9] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98121 USA

[10] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA

[11] Tabriz Univ Med Sci, Aging Res Inst, Tabriz, Iran

[12] Tabriz Univ Med Sci, Dept Community Med, Tabriz, Iran

[13] Tabriz Univ Med Sci, Dept Pharmacol & Toxicol, Tabriz, Iran

[14] Jahrom Univ Med Sci, Dept Parasitol & Mycol, Jahrom, Iran

[15] Karolinska Univ Hosp, LABMED, Stockholm, Sweden

[16] Dept Epidemiol, Tehran, Iran

[17] Hlth Management & Econ Res Ctr, Tehran, Iran

[18] Iran Univ Med Sci, Hlth Econ Dept, Tehran, Iran

[19] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran

[20] King Saud Univ, Coll Med, Riyadh, Saudi Arabia

[21] McGill Univ, Div Gastroenterol & Hepatol, Montreal, PQ, Canada

[22] Univ Lahore, Univ Inst Publ Hlth, Lahore, Pakistan

[23] Univ Hail, Coll Publ Hlth, Hail, Saudi Arabia

[24] Indian Inst Publ Hlth, Gaudhinagar, India

[25] Publ Hlth Fdn India, Gurugram, India

[26] Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, Canada

[27] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada

[28] Univ Sultan Zainal Abidin, Biomed Dept, Kuala Terengganu, Malaysia

[29] Univ Sultan Zainal Abidin, Unit Biochem, Fac Med, Kuala Terengganu, Malaysia

[30] Queen Elizabeth Hosp Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England

[31] Queen Elizabeth Hosp Birmingham, Inst Translat Med, Birmingham, W Midlands, England

[32] Univ Birmingham, IAHR ITM, Birmingham, W Midlands, England

[33] Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Babol Sar, Iran

[34] Univ Catania, Dept Gen Surg & Med Surg Specialties, Catania, Italy

[35] Univ Catania, Gen Surg & Med Surg Specialties, Catania, Italy

[36] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA

[37] Univ Porto, Appl Mol Biosci Unit, Porto, Portugal

[38] Univ Porto, Inst Publ Hlth, Porto, Portugal

[39] Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, Iran

[40] UN, World Food Programme, New Delhi, India

[41] Maragheh Univ Med Sci, Dept Microbiol, Maragheh, Iran

[42] Maragheh Univ Med Sci, Pharmacol & Toxicol Dept, Maragheh, Iran

[43] Catholic Univ Portugal, Ctr Biotechnol & Fine Chem, Porto, Portugal

[44] Univ Porto, REQUIMTE LAQV, Porto, Portugal

[45] Bielefeld Univ, Sch Publ Hlth Med, Bielefeld, Germany

[46] Shahid Beheshti Univ Med Sci, Dept Med & Pharmaceut Chem, Tehran, Iran

[47] Shahid Beheshti Univ Med Sci, Dept Pharmacol, Tehran, Iran

[48] Shahid Beheshti Univ Med Sci, Obes Res Ctr, Tehran, Iran

[49] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA

[50] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA

来源：

LANCET GASTROENTEROLOGY & HEPATOLOGY | 2020年 / 5卷 / 01期

关键词：

ULCERATIVE-COLITIS; CROHNS-DISEASE; RISK-FACTORS; EPIDEMIOLOGY; POPULATION; PREVALENCE; MANAGEMENT; DIAGNOSIS; COHORT; IBD;

D O I：

10.1016/S2468-1253(19)30333-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Background The burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and trends of disease in different countries and regions. Understanding these geographical differences is crucial for formulating effective strategies for preventing and treating IBD. We report the prevalence, mortality, and overall burden of IBD in 195 countries and territories between 1990 and 2017, based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. Methods We modelled mortality due to IBD using a standard Cause of Death Ensemble model including data mainly from vital registrations. To estimate the non-fatal burden, we used data presented in primary studies, hospital discharges, and claims data, and used DisMod-MR 2.1, a Bayesian meta-regression tool, to ensure consistency between measures. Mortality, prevalence, years of life lost (YLLs) due to premature death, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were estimated. All of the estimates were reported as numbers and rates per 100 000 population, with 95% uncertainty intervals (UI). Findings In 2017, there were 6.8 million (95% UI 6.4-7.3) cases of IBD globally. The age-standardised prevalence rate increased from 79.5 (75.9-83.5) per 100 000 population in 1990 to 84.3 (79.2-89.9) per 100 000 population in 2017. The age-standardised death rate decreased from 0.61 (0.55-0.69) per 100 000 population in 1990 to 0.51 (0.42-0.54) per 100 000 population in 2017. At the GBD regional level, the highest age-standardised prevalence rate in 2017 occurred in high-income North America (422.0 [398.7-446.1] per 100 000) and the lowest age-standardised prevalence rates were observed in the Caribbean (6.7 [6.3-7.2] per 100 000 population). High Sociodemographic Index (SDI) locations had the highest age-standardised prevalence rate, while low SDI regions had the lowest age-standardised prevalence rate. At the national level, the USA had the highest age-standardised prevalence rate (464.5 [438.6-490.9] per 100 000 population), followed by the UK (449.6 [420.6-481.6] per 100 000). Vanuatu had the highest age-standardised death rate in 2017 (1.8 [0.8-3.2] per 100 000 population) and Singapore had the lowest (0.08 [0.06-0.14] per 100 000 population). The total YLDs attributed to IBD almost doubled over the study period, from 0.56 million (0.39-0.77) in 1990 to 1.02 million (0.71-1.38) in 2017. The age-standardised rate of DALYs decreased from 26.5 (21.0-33.0) per 100 000 population in 1990 to 23.2 (19.1-27.8) per 100 000 population in 2017. Interpretation The prevalence of IBD increased substantially in many regions from 1990 to 2017, which might pose a substantial social and economic burden on governments and health systems in the coming years. Our findings can be useful for policy makers developing strategies to tackle IBD, including the education of specialised personnel to address the burden of this complex disease. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

引用

页码：17 / 30

页数：14

共 32 条

[1]

Environmental risk factors for inflammatory bowel diseases: Evidence based literature review [J].